{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:10:27Z","timestamp":1790179827433,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T00:00:00Z","timestamp":1729987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T00:00:00Z","timestamp":1729987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Health and social care Research","award":["NIHR302291"],"award-info":[{"award-number":["NIHR302291"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Children continue to experience chemotherapy-induced nausea and vomiting (CINV), despite effective antiemetic medications. Recommendations in clinical practice guidelines are underpinned by narrative syntheses and meta-analyses that compare only two treatments. This means not all antiemetics have been compared to one another, and estimates remain imprecise. We apply network meta-analysis (NMA) to overcome these limitations by comparing multiple treatments simultaneously.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic review identified and critically appraised RCTs comparing antiemetics recommended and licensed for the prevention of CINV in children. Bayesian NMA compared and ranked antiemetic effectiveness for the outcomes complete (CR) and partial response (PR) in the acute, delayed, and overall phases, nausea, and decreased food intake. Antiemetics given with and without dexamethasone were compared in separate networks as their underlying populations differed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixteen RCTs (3115 patients receiving moderately (MEC) or highly emetogenic chemotherapy (HEC)) were included. When given with dexamethasone, NK1 antagonists with ondansetron ranked highest for CR and PR in the acute and overall phases, PR in the delayed phase, and decreased food intake. Post hoc analysis shows further a benefit of adding olanzapine to regimens of aprepitant and ondansetron. Ondansetron ranked lower than palonosetron, for CR in the delayed and overall phases, and ondansetron was less effective than palonosetron for nausea prevention. Rankings for other regimens, including those given without dexamethasone, were uncertain or inconsistent across outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings serve to support the current recommendations of olanzapine (when given with aprepitant and ondansetron) and NK1 antagonists\u2019 regimens receiving HEC, but note that evidence of a significant difference in relative benefit, between patients receiving MEC and HEC, does not yet exist. Recommendations for palonosetron as the preferred 5HT3 antagonists may be extended, particularly, to those who are at high risk of nausea.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-024-08939-9","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T08:41:13Z","timestamp":1730104873000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antiemetic medications for preventing chemotherapy-induced nausea and vomiting in children: a systematic review and Bayesian network meta-analysis"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2765-7363","authenticated-orcid":false,"given":"R.","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,27]]},"reference":[{"key":"8939_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/jpon.2003.76","volume":"20","author":"M Hedstr\u00f6m","year":"2003","unstructured":"Hedstr\u00f6m M, Haglund K, Skolin I, von Essen L (2003) Distressing events for children and adolescents with cancer: child, parent, and nurse perceptions. J Pediatr Oncol Nurs 20:120\u201332","journal-title":"J Pediatr Oncol Nurs"},{"key":"8939_CR2","doi-asserted-by":"publisher","unstructured":"Phillips RS, Gibson F, Houghton E, Gopaul S, Craig JV, Pizer B (2016) Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood (an update). Cochrane Database Syst Rev 2(2). https:\/\/doi.org\/10.1002\/14651858.CD007786.pub3","DOI":"10.1002\/14651858.CD007786.pub3"},{"key":"8939_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-3-662-44317-0_10","volume-title":"Nausea and vomiting. Supportive care in pediatric oncology: a practical evidence-based approach","author":"T Chang","year":"2015","unstructured":"Chang T (2015) Nausea and vomiting. Supportive care in pediatric oncology: a practical evidence-based approach, 1st edn. Springer Berlin Heidelberg Imprint Springer, pp 159\u2013175","edition":"1"},{"issue":"5","key":"8939_CR4","doi-asserted-by":"publisher","first-page":"e27646","DOI":"10.1002\/pbc.27646","volume":"66","author":"E Paw Cho Sing","year":"2019","unstructured":"Paw Cho Sing E, Robinson PD, Flank J, Holdsworth M, Thackray J, Freedman J, Gibson P, Orsey AD, Patel P, Phillips R, Portwine C, Raybin JL, Cabral S, Sung L, Dupuis LL (2019) Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. Pediatr Blood Cancer 66(5):e27646","journal-title":"Pediatr Blood Cancer"},{"key":"8939_CR5","doi-asserted-by":"publisher","unstructured":"Patel P, Robinson, PD, Cohen, M et al (2022) Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: a clinical practice guideline. Pediatr Blood Cancer 69. https:\/\/doi.org\/10.1002\/pbc.30001","DOI":"10.1002\/pbc.30001"},{"key":"8939_CR6","doi-asserted-by":"publisher","unstructured":"Patel P, Robinson PD, Devine KA, Positano K, Cohen M, Gibson P, Holdsworth M, Phillips R, Spinelli D, Thackray J, van de Wetering M, Woods D, Cabral S, Sung L, Dupuis LL (2021) Prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: clinical practice guideline update. Pediatr Blood Cancer 68. https:\/\/doi.org\/10.1002\/pbc.28947","DOI":"10.1002\/pbc.28947"},{"key":"8939_CR7","doi-asserted-by":"publisher","unstructured":"Patel P RP, Thackray J, Flank J, Holdsworth MT, Gibson P et al (2017) Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. Pediaticr Blood Cancer 64. https:\/\/doi.org\/10.1002\/pbc.26542","DOI":"10.1002\/pbc.26542"},{"key":"8939_CR8","doi-asserted-by":"crossref","unstructured":"Dupuis LLSL, Molassiotis A, Orsey AD, Tissing W, van de Wetering M (2017) MASCC\/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children. 2017(25):323-31","DOI":"10.1007\/s00520-016-3384-y"},{"key":"8939_CR9","unstructured":"CCLG CsCaLG (2018) Guideline on the management of chemotherapy induced nausea and vomiting. Available from: https:\/\/www.piernetwork.org\/uploads\/4\/7\/8\/1\/47810883\/cclg_cinv_guideline_march_2018.pdf.\u00a0 Accessed Aug 2024"},{"issue":"24","key":"8939_CR10","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38(24):2782\u20132797","journal-title":"J Clin Oncol"},{"issue":"28","key":"8939_CR11","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(28):3240\u20133261","journal-title":"J Clin Oncol"},{"issue":"2","key":"8939_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/pbc.23114","volume":"57","author":"LLBS Dupuis","year":"2011","unstructured":"Dupuis LLBS, Sung L, Portwine C, Hain R, McCarthy P, Holdsworth M, Pediatric Oncology Group of Ontario (2011) Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 57(2):191\u20138","journal-title":"Pediatr Blood Cancer"},{"key":"8939_CR13","first-page":"CD007786","volume":"9","author":"RS Phillips","year":"2010","unstructured":"Phillips RS, Gopaul S, Gibson F, Houghton E, Craig JV, Light K et al (2010) Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev 9:CD007786","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"8939_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/wvn.12209","volume":"14","author":"SBM Crane","year":"2017","unstructured":"Crane SBM (2017) Understanding ethical issues of research participation from the perspective of participating children and adolescents: a systematic review. Worldviews Evid Based Nurs 14(3):200\u2013209","journal-title":"Worldviews Evid Based Nurs"},{"key":"8939_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/pr.2015.75","volume":"78","author":"F Bloomfield","year":"2015","unstructured":"Bloomfield F (2015) The challenges of research participation by children. Pediatr Res 78:109\u2013110","journal-title":"Pediatr Res"},{"key":"8939_CR16","doi-asserted-by":"publisher","first-page":"e715","DOI":"10.1136\/bmjspcare-2018-001521","volume":"12","author":"JNBE Peake","year":"2022","unstructured":"Peake JNBE, Oostendorp LJM et al (2022) Research barriers in children and young people with life-limiting conditions: a surve. BMJ Support Palliat Care 12:e715\u2013e721","journal-title":"BMJ Support Palliat Care"},{"key":"8939_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/9781118951651","volume-title":"Network meta-analysis for decision making","author":"SWN Dias","year":"2018","unstructured":"Dias SWN, Jansen JP, Sutton A (2018) Network meta-analysis for decision making. Wiley"},{"issue":"11","key":"8939_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"key":"8939_CR19","unstructured":"Rohatgi A (2022) WebPlotDigitizer version 4.6. Available from: https:\/\/automeris.io\/WebPlotDigitizer. Accessed Aug 2024"},{"key":"8939_CR20","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"8939_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/jrsm.1193","volume":"7","author":"KM Rhodes","year":"2016","unstructured":"Rhodes KM, Turner RM, Higgins JP (2016) T Empirical evidence about inconsistency among studies in a pair-wise meta-analysis. Res Syn Meth 7:346\u2013370","journal-title":"Res Syn Meth"},{"key":"8939_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s005200050027","volume":"8","author":"C Forni","year":"2000","unstructured":"Forni C, Ferrari S, Loro L, Mazzei T, Beghelli C, Biolchini A, Simoni P, Tremosini M, Strazzari S, Puggioli C, Bacci G (2000) Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. Support Care Cancer 8:131\u2013133","journal-title":"Support Care Cancer"},{"key":"8939_CR23","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s004310050940","volume":"157","author":"V Koseoglu","year":"1998","unstructured":"Koseoglu V, Kurekci AE, Sarici U, Atay AA, Ozcan O (1998) Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. Eur J Pediatr 157:806\u2013810","journal-title":"Eur J Pediatr"},{"key":"8939_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1590\/S1516-31802006000200003","volume":"124","author":"FA Luisi","year":"2006","unstructured":"Luisi FA, Petrilli AS, Tanaka C, Caran EM (2006) Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma. Sao Paulo Med J 124:61\u201365","journal-title":"Sao Paulo Med J"},{"issue":"6","key":"8939_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.arcmed.2008.04.007","volume":"39","author":"AC Sepulveda-Vildosola","year":"2008","unstructured":"Sepulveda-Vildosola AC, Betanzos-Cabrera Y, Lastiri GG, Rivera-Marquez H, Villasis-Keever MA, Del Angel VW et al (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 39(6):601\u2013606","journal-title":"Arch Med Res"},{"key":"8939_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/00043426-199505000-00008","volume":"17","author":"O Alvarez","year":"1995","unstructured":"Alvarez O, Freeman A, Bedros A, Call SK, Volsch J, Kalbermatter O, Halverson J, Convy L, Cook L, Mick K et al (1995) Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 17:145\u2013150","journal-title":"J Pediatr Hematol Oncol"},{"issue":"10","key":"8939_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s00520-007-0242-y","volume":"15","author":"SG Berrak","year":"2007","unstructured":"Berrak SG, Ozdemir N, Bakirci N, Turkkan E, Canpolat C, Beker B et al (2007) A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy. Support Care Cancer 15(10):1163\u20131168","journal-title":"Support Care Cancer"},{"issue":"10","key":"8939_CR28","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s00520-011-1376-5","volume":"20","author":"FB Cakir","year":"2012","unstructured":"Cakir FB, Yapar O, Canpolat C, Akalin F, Berrak SG (2012) Cardiac effects of granisetron in a prospective crossover randomized dose comparison trial. Support Care Cancer 20(10):2451\u20132457","journal-title":"Support Care Cancer"},{"issue":"3","key":"8939_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/08880010490427351","volume":"21","author":"TH Jaing","year":"2004","unstructured":"Jaing TH, Tsay PK, Hung IJ, Yang CP, Hu WY (2004) Single-dose oral granisetron versus multidose intravenous ondansetron for moderately emetogenic cyclophosphamide-based chemotherapy in pediatric outpatients with acute lymphoblastic leukemia. Pediatr Hematol Oncol 21(3):227\u2013235","journal-title":"Pediatr Hematol Oncol"},{"key":"8939_CR30","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S0959-8049(99)00071-4","volume":"35","author":"Y Komada","year":"1999","unstructured":"Komada Y, Matsuyama T, Takao A, Hongo T, Nishimura Y, Horibe K, Sakurai M (1999) A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy. Eur J Cancer 35:1095\u20131101","journal-title":"Eur J Cancer"},{"issue":"6","key":"8939_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.12788\/jcso.0139","volume":"13","author":"V Patil","year":"2015","unstructured":"Patil V, Prasada H, Prasad K, Shenoy UV (2015) Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children. J Community Support Oncol 13(6):209\u2013213","journal-title":"J Community Support Oncol"},{"issue":"2","key":"8939_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/088800199277425","volume":"16","author":"E Stiakaki","year":"1999","unstructured":"Stiakaki E, Savvas S, Lydaki E, Bolonaki I, Kouvidi E, Dimitriou H et al (1999) Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol 16(2):101\u2013108","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"8939_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.htct.2022.02.004","volume":"45","author":"A Eghbali","year":"2023","unstructured":"Eghbali A, Kohpar FK, Ghaffari K, Afzal RR, Eghbali A, Ghasemi A (2023) Evaluating aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: a triple-blinded randomized clinical trial. Hematol Transfus Cell Ther 45(3):281\u2013289","journal-title":"Hematol Transfus Cell Ther"},{"key":"8939_CR34","first-page":"673","volume":"14","author":"Y Tsuchida","year":"1999","unstructured":"Tsuchida Y, Hayashi Y, Asami K, Yamamoto K, Yokoyama J, Mugishima H, Honna T, Mimaya J, Hara F, Sawada T, Matsumura T, Suita S, Sugimoto T, Kaneko M (1999) Effects of granisetron in children undergoing high-dose chemotherapy: a multi-institutional, cross-over study. Int J Oncol 14:673\u2013679","journal-title":"Int J Oncol"},{"key":"8939_CR35","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/0959-8049(96)00157-8","volume":"32","author":"P Brock","year":"1996","unstructured":"Brock P, Brichard B, Rechnitzer C, Langeveld NE, Lanning M, Soderhall S, Laurent C (1996) An increased loading dose of ondansetron: a North European, double-blind randomised study in children, comparing 5 mg\/m2 with 10 mg\/m2. Eur J Cancer 32:1744\u20131748","journal-title":"Eur J Cancer"},{"issue":"5","key":"8939_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/07357909909032871","volume":"17","author":"C Sandoval","year":"1999","unstructured":"Sandoval C, Corbi D, Strobino B, Fevzi Ozkaynak M, Tugal O, Jayabose S (1999) Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients. Cancer Invest 17(5):309\u2013313","journal-title":"Cancer Invest"},{"issue":"6","key":"8939_CR37","doi-asserted-by":"publisher","first-page":"e29002","DOI":"10.1002\/pbc.29002","volume":"68","author":"J Ruktrirong","year":"2021","unstructured":"Ruktrirong J, Traivaree C, Monsereenusorn C, Photia A, Lertvivatpong N, Rujkijyanont P (2021) Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: a comparative randomized double-blind controlled trial. Pediatr Blood Cancer 68(6):e29002","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"8939_CR38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/08880010050120791","volume":"17","author":"L White","year":"2000","unstructured":"White L, Daly SA, McKenna CJ, Zhestkova N, Leal C, Breatnach F et al (2000) A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately\/highly emetogenic chemotherapy. Pediatr Hematol Oncol 17(6):445\u2013455","journal-title":"Pediatr Hematol Oncol"},{"issue":"22","key":"8939_CR39","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1200\/JCO.20.00134","volume":"1","author":"LLTG Dupuis","year":"2020","unstructured":"Dupuis LLTG, Pong A, Sung L, Bickham K, A Pooled Anal (2020) Factors associated with chemotherapy-induced vomiting control in pediatric patients receiving moderately or highly emetogenic chemotherapy: a pooled analysis. J Clin Oncol 1(22):2499\u2013509","journal-title":"J Clin Oncol"},{"issue":"4","key":"8939_CR40","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1470-2045(15)70061-6","volume":"16","author":"HJ Kang","year":"2015","unstructured":"Kang HJ, Loftus S, Taylor A, DiCristina C, Green S, Zwaan CM (2015) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet Oncol 16(4):385\u2013394","journal-title":"Lancet Oncol"},{"key":"8939_CR41","unstructured":"BMJ. British National Formulary (online) London. Joint Formulary Committee. British National Formulary: BMJ and pharmaceutical Press. Available from: http:\/\/www.medicinescomplete.com\u00a0Accessed Aug 2024"},{"key":"8939_CR42","doi-asserted-by":"publisher","unstructured":"Sra MS, Ganguly S, Naik RD, Sasi A, Sharma P, Giri RK et al (2023) Olanzapine cost-effectiveness in vomiting and nausea from highly emetogenic chemotherapy in children and adolescents. BMJ Support Palliat Care. https:\/\/doi.org\/10.1136\/spcare-2022-004069","DOI":"10.1136\/spcare-2022-004069"},{"key":"8939_CR43","unstructured":"NICE (2024) British National Formulary (BNF). Available from: https:\/\/bnf.nice.org.uk\/drugs\/palonosetron\/medicinal-forms\/.\u00a0Accessed Aug 2024"},{"issue":"10","key":"8939_CR44","doi-asserted-by":"publisher","first-page":"e29795","DOI":"10.1002\/pbc.29795","volume":"69","author":"MS Sra","year":"2022","unstructured":"Sra MS, Ganguly S, Sasi A, Sharma P, Giri RK, Rasheed AA et al (2022) Cost-effectiveness analysis of aprepitant-based anti-emetic regimen for children receiving highly emetogenic chemotherapy: individual patient data analysis of a randomized trial. Pediatr Blood Cancer 69(10):e29795","journal-title":"Pediatr Blood Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08939-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08939-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08939-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T09:11:23Z","timestamp":1731489083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08939-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,27]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["8939"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08939-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,27]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a secondary analysis of published randomised control trial data. A research ethics committee at the University of York has confirmed no ethical approval is needed for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"747"}}